Back to resultsA Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
Primary Purpose
Glioblastoma
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Bevacizumab
Onartuzumab
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Glioblastoma
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed glioblastoma at first recurrence after concurrent or adjuvant chemoradiotherapy
- Imaging confirmation of first tumor progression or regrowth as defined by RANO criteria
- Prior treatment with temozolomide
- No more than one prior line of chemotherapy
- No prior treatment with bevacizumab or other vascular endothelial growth factor (VEGF)- or VEGF-receptor-targeted agent
- No prior exposure to experimental treatment targeting either hepatocyte growth factor (HGF) or Met pathway
- No prior treatment with prolifeprospan 20 with carmustine wafer
- No prior intracerebral agent
- Recovery from the toxic effects of prior therapy
- No evidence of recent hemorrhage on baseline magnetic resonance imaging (MRI) of the brain
- No need for urgent palliative intervention for primary disease (e.g. impending herniation)
- Karnofsky performance status greater than or equal to (>=) 70 percent (%)
- Stable or decreasing dose of corticosteroids within 5 days prior to randomization
- Prior therapy with gamma knife or other focal high-dose radiotherapy is allowed, but the participant must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field
- Participants who have undergone recent surgery for recurrent or progressive tumor are eligible provided that: surgery must have confirmed the recurrence, a minimum of 28 days must have elapsed from the day of surgery to randomization and for core or needle biopsy, a minimum of 7 days must have elapsed prior to randomization, and craniotomy or intracranial biopsy site must be adequately healed and free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of randomization
- Availability of formalin fixed paraffin embedded tumor tissue representative of glioblastoma
Exclusion Criteria:
- Pregnant or lactating women
- Inadequate hematologic, renal or liver function
- History or presence of serious cardio-vascular disease
- New York Heart Association Grade II or greater congestive heart failure
- History of another malignancy in the previous 3 years, except for in situ cancer or basal or squamous cell skin cancer
- Inadequately controlled hypertension (defined as systolic blood pressure greater than [>]150 millimeter of mercury (mmHg) and/or diastolic blood pressure >100 mmHg while on antihypertensive medication)
- Prior history of hypertensive crisis or hypertensive encephalopathy
- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to randomization
- Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
- Known hypersensitivity to any excipients of onartuzumab or bevacizumab
Sites / Locations
- University of Alabama At Birmingham; Neuro-Oncology
- Cedars Sinai Medical Center; Neurosurgery
- UCLA
- USCF - Neurosurgery
- Stanford Comprehensive Cancer Center
- University of Colorado
- Florida Cancer Specialists - Englewood
- Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
- Moffitt Cancer Center
- North Western Univ; Neurology
- Northshore University Health System; Cardiology
- Henry Ford Health System
- Duke University Medical Center
- Hatton Research Institutes
- Sarah Cannon Cancer Center - Tennessee Oncology, Pllc
- Baylor Research Inst.
- University of Virgina
- Virginia Cancer Institute
- Seattle Cancer Care Alliance; Investigational Drug Service
- Hamilton Health Sciences - Juravinski Cancer Centre
- London Health Sciences Centre
- Sunnybrook Health Science Centre
- Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727
- McGill University; Montreal Neurological Institute; Oncology
- CHUS Hopital Fleurimont; CRC
- Hopital Avicenne; Neurologie
- Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie
- Hopital Roger Salengro
- Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage
- Centre Val Aurelle Paul Lamarque; Medecine B3
- Hôpital Central; Departement de Neuro-Oncologie
- Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin
- Ico Rene Gauducheau; Oncologie
- Hopital Purpan
- Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin
- Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie
- Universitatsklinikum Hamburg-Eppendorf; Klinik und Poliklinik fur Neurochirurgie
- Ärztehaus Velen
- Universitätsklinikum Köln
- Klinikum der Johannes Gutenberg Uni Mainz; Studienz. Neurologie, Klinik und Poliklinik Neurologie
- Uni Klinikum München - Großhardern; Med. Klinik U. Poliklinik III - Abt. Onkologie u. Hämatologie
- Pius-Hospital
- Ospedale Bellaria; U.O. Oncologia Medica
- Presidio Ospedaliero Marconi Bufalini; U.O. di Oncologia
- A.O. Universitaria Di Parma; Oncologia Medica
- Spedali Civili di Brescia
- Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
- Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica
- Azienda Ospedaliera Città della Salute e della Scienza di Torino
- Az. Osp. Pisana Ospedale S. Chiara; U.O. Di Reumatologia
- Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
- Clinica Universitaria de Navarra; Servicio de Oncologia
- Hospital Clinic i Provincial; Servicio de Farmacia
- Institut Catala d Oncologia Hospital Duran i Reynals
- Hospital Ramon y Cajal; Servicio de Oncologia
- HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
- Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
- HUG; Oncologie
- Universitätsspital Zürich; Klinik für Neurologie
- Bristol Haematology and Oncology Centre
- Sarah Cannon Research Institute
- Nottingham City Hospital; David Evans Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Onartuzumab + Bevacizumab
Placebo + Bevacizumab
Arm Description
All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
Outcomes
Primary Outcome Measures
Progression-free survival (PFS) as Assessed by Investigator According to Response Assessment in Neuro-Oncology (RANO) Criteria
Progression-free survival (PFS) as Assessed by Investigator According to RANO Criteria (in Participants With Met-Positive Glioblastoma)
Secondary Outcome Measures
Overall Survival (All Participants)
Percentage of Participants who Survived at Month 9 (All Participants)
Percentage of Participants who are Progression Free at Month 6, as Assessed by RANO Criteria (All Participants)
Percentage of Participants With Objective Response (OR), as Assessed by RANO Criteria (All Participants)
Duration of Response, as Assessed by RANO Criteria
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of Participants With Serum Anti-Therapeutic Antibody (ATAs) to Onartuzumab
Overall Survival (in Participants With Met-Positive Glioblastoma)
Percentage of Participants who Survived at Month 9 (in Participants With Met-Positive Glioblastoma)
Percentage of Participants who are Progression Free at Month 6, as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)
Percentage of Participants With Objective Response (OR), as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)
Duration of Response, as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in Participants With Met-Positive Glioblastoma
Minimum Observed Serum Concentration (Cmin) of Onartuzumab
Maximum Observed Serum Concentration (Cmax) of Onartuzumab
Minimum Observed Serum Concentration (Cmin) of Bevacizumab
Maximum Observed Serum Concentration (Cmax) of Bevacizumab
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01632228
Brief Title
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
June 29, 2012 (Actual)
Primary Completion Date
January 21, 2016 (Actual)
Study Completion Date
January 21, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent glioblastoma. Participants will be randomized 1:1 to receive either placebo plus bevacizumab every 3 weeks, or onartuzumab plus bevacizumab. Study treatment will continue until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioblastoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
135 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Onartuzumab + Bevacizumab
Arm Type
Experimental
Arm Description
All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
Arm Title
Placebo + Bevacizumab
Arm Type
Active Comparator
Arm Description
All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
Intervention Type
Drug
Intervention Name(s)
Bevacizumab
Intervention Description
Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Intervention Type
Drug
Intervention Name(s)
Onartuzumab
Other Intervention Name(s)
MetMAb, RO5490258
Intervention Description
Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Primary Outcome Measure Information:
Title
Progression-free survival (PFS) as Assessed by Investigator According to Response Assessment in Neuro-Oncology (RANO) Criteria
Time Frame
Baseline until disease progression, intolerable toxicity, participant or physician decision, or death, whichever occurs first (assessed every 6 weeks up to 18 months)
Title
Progression-free survival (PFS) as Assessed by Investigator According to RANO Criteria (in Participants With Met-Positive Glioblastoma)
Time Frame
Baseline until disease progression, intolerable toxicity, participant or physician decision, or death, whichever occurs first (assessed every 6 weeks up to 18 months)
Secondary Outcome Measure Information:
Title
Overall Survival (All Participants)
Time Frame
Baseline until death (up to approximately 18 months)
Title
Percentage of Participants who Survived at Month 9 (All Participants)
Time Frame
Month 9
Title
Percentage of Participants who are Progression Free at Month 6, as Assessed by RANO Criteria (All Participants)
Time Frame
Month 6
Title
Percentage of Participants With Objective Response (OR), as Assessed by RANO Criteria (All Participants)
Time Frame
Baseline until disease progression, intolerable toxicity, participant or physician decision, or death, whichever occurs first (assessed every 6 weeks up to 18 months)
Title
Duration of Response, as Assessed by RANO Criteria
Time Frame
Baseline until disease progression, intolerable toxicity, participant or physician decision, or death, whichever occurs first (assessed every 6 weeks up to 18 months)
Title
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame
Baseline up to approximately 3 years 8 months
Title
Percentage of Participants With Serum Anti-Therapeutic Antibody (ATAs) to Onartuzumab
Time Frame
Predose (0 hour) on Day 1 of Cycles 1, 2, 3, 4, at study completion or study drug discontinuation visit (up to approximately 3.5 years; Cycle length: 21 days)
Title
Overall Survival (in Participants With Met-Positive Glioblastoma)
Time Frame
Baseline until death (up to approximately 18 months)
Title
Percentage of Participants who Survived at Month 9 (in Participants With Met-Positive Glioblastoma)
Time Frame
Month 9
Title
Percentage of Participants who are Progression Free at Month 6, as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)
Time Frame
Month 6
Title
Percentage of Participants With Objective Response (OR), as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)
Time Frame
Baseline until disease progression, intolerable toxicity, participant or physician decision, or death, whichever occurs first (assessed every 6 weeks up to 18 months)
Title
Duration of Response, as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)
Time Frame
Baseline until disease progression, intolerable toxicity, participant or physician decision, or death, whichever occurs first (assessed every 6 weeks up to 18 months)
Title
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in Participants With Met-Positive Glioblastoma
Time Frame
Baseline up to approximately 3 years 8 months
Title
Minimum Observed Serum Concentration (Cmin) of Onartuzumab
Time Frame
predose (0 hour) on Day 1 of Cycles 1, 2, 3, 4, at study completion or study drug discontinuation visit (up to approximately 3.5 years) (Cycle length: 21 days; infusion duration: Onartuzumab 60 minutes)
Title
Maximum Observed Serum Concentration (Cmax) of Onartuzumab
Time Frame
predose (0 hour) and 30 minutes post dose on Day 1 of Cycles 1, 2, 3, 4, at study completion or study drug discontinuation visit (up to approximately 3.5 years) (Cycle length: 21 days; infusion duration: Onartuzumab 60 minutes)
Title
Minimum Observed Serum Concentration (Cmin) of Bevacizumab
Time Frame
predose (0 hour) on Day 1 of Cycles 1, 2, 3, 4, at study completion or study drug discontinuation visit (up to approximately 3.5 years) (Cycle length: 21 days; infusion duration: Bevacizumab 90 minutes)
Title
Maximum Observed Serum Concentration (Cmax) of Bevacizumab
Time Frame
predose (0 hour) and 30 minutes post dose on Day 1 of Cycles 1, 2, 3, 4, at study completion or study drug discontinuation visit (up to approximately 3.5 years) (Cycle length: 21 days; infusion duration: Bevacizumab 90 minutes)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed glioblastoma at first recurrence after concurrent or adjuvant chemoradiotherapy
Imaging confirmation of first tumor progression or regrowth as defined by RANO criteria
Prior treatment with temozolomide
No more than one prior line of chemotherapy
No prior treatment with bevacizumab or other vascular endothelial growth factor (VEGF)- or VEGF-receptor-targeted agent
No prior exposure to experimental treatment targeting either hepatocyte growth factor (HGF) or Met pathway
No prior treatment with prolifeprospan 20 with carmustine wafer
No prior intracerebral agent
Recovery from the toxic effects of prior therapy
No evidence of recent hemorrhage on baseline magnetic resonance imaging (MRI) of the brain
No need for urgent palliative intervention for primary disease (e.g. impending herniation)
Karnofsky performance status greater than or equal to (>=) 70 percent (%)
Stable or decreasing dose of corticosteroids within 5 days prior to randomization
Prior therapy with gamma knife or other focal high-dose radiotherapy is allowed, but the participant must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field
Participants who have undergone recent surgery for recurrent or progressive tumor are eligible provided that: surgery must have confirmed the recurrence, a minimum of 28 days must have elapsed from the day of surgery to randomization and for core or needle biopsy, a minimum of 7 days must have elapsed prior to randomization, and craniotomy or intracranial biopsy site must be adequately healed and free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of randomization
Availability of formalin fixed paraffin embedded tumor tissue representative of glioblastoma
Exclusion Criteria:
Pregnant or lactating women
Inadequate hematologic, renal or liver function
History or presence of serious cardio-vascular disease
New York Heart Association Grade II or greater congestive heart failure
History of another malignancy in the previous 3 years, except for in situ cancer or basal or squamous cell skin cancer
Inadequately controlled hypertension (defined as systolic blood pressure greater than [>]150 millimeter of mercury (mmHg) and/or diastolic blood pressure >100 mmHg while on antihypertensive medication)
Prior history of hypertensive crisis or hypertensive encephalopathy
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to randomization
Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
Known hypersensitivity to any excipients of onartuzumab or bevacizumab
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama At Birmingham; Neuro-Oncology
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Cedars Sinai Medical Center; Neurosurgery
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
USCF - Neurosurgery
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Stanford Comprehensive Cancer Center
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
University of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Florida Cancer Specialists - Englewood
City
Englewood
State/Province
Florida
ZIP/Postal Code
34223
Country
United States
Facility Name
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33647
Country
United States
Facility Name
North Western Univ; Neurology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Northshore University Health System; Cardiology
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Hatton Research Institutes
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45220
Country
United States
Facility Name
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Baylor Research Inst.
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
University of Virgina
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Facility Name
Virginia Cancer Institute
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23226
Country
United States
Facility Name
Seattle Cancer Care Alliance; Investigational Drug Service
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States
Facility Name
Hamilton Health Sciences - Juravinski Cancer Centre
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 5C2
Country
Canada
Facility Name
London Health Sciences Centre
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 4L6
Country
Canada
Facility Name
Sunnybrook Health Science Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Facility Name
Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
McGill University; Montreal Neurological Institute; Oncology
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 2B4
Country
Canada
Facility Name
CHUS Hopital Fleurimont; CRC
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Facility Name
Hopital Avicenne; Neurologie
City
Bobigny
ZIP/Postal Code
93009
Country
France
Facility Name
Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie
City
Bron
ZIP/Postal Code
69677
Country
France
Facility Name
Hopital Roger Salengro
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage
City
Marseille
ZIP/Postal Code
13385
Country
France
Facility Name
Centre Val Aurelle Paul Lamarque; Medecine B3
City
Montpellier
ZIP/Postal Code
34298
Country
France
Facility Name
Hôpital Central; Departement de Neuro-Oncologie
City
Nancy
ZIP/Postal Code
54000
Country
France
Facility Name
Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin
City
Paris
ZIP/Postal Code
75651
Country
France
Facility Name
Ico Rene Gauducheau; Oncologie
City
Saint Herblain
ZIP/Postal Code
44805
Country
France
Facility Name
Hopital Purpan
City
Toulouse Cedex 9
ZIP/Postal Code
31059
Country
France
Facility Name
Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie
City
Frankfurt am Main
ZIP/Postal Code
60528
Country
Germany
Facility Name
Universitatsklinikum Hamburg-Eppendorf; Klinik und Poliklinik fur Neurochirurgie
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
Ärztehaus Velen
City
Ibbenbühren
ZIP/Postal Code
49479
Country
Germany
Facility Name
Universitätsklinikum Köln
City
Köln
ZIP/Postal Code
50937
Country
Germany
Facility Name
Klinikum der Johannes Gutenberg Uni Mainz; Studienz. Neurologie, Klinik und Poliklinik Neurologie
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Uni Klinikum München - Großhardern; Med. Klinik U. Poliklinik III - Abt. Onkologie u. Hämatologie
City
München
ZIP/Postal Code
81377
Country
Germany
Facility Name
Pius-Hospital
City
Oldenburg
ZIP/Postal Code
26121
Country
Germany
Facility Name
Ospedale Bellaria; U.O. Oncologia Medica
City
Bologna
State/Province
Emilia-Romagna
ZIP/Postal Code
40133
Country
Italy
Facility Name
Presidio Ospedaliero Marconi Bufalini; U.O. di Oncologia
City
Cesena
State/Province
Emilia-Romagna
ZIP/Postal Code
47023
Country
Italy
Facility Name
A.O. Universitaria Di Parma; Oncologia Medica
City
Parma
State/Province
Emilia-Romagna
ZIP/Postal Code
43100
Country
Italy
Facility Name
Spedali Civili di Brescia
City
Brescia
State/Province
Lombardia
ZIP/Postal Code
25123
Country
Italy
Facility Name
Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20122
Country
Italy
Facility Name
Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Facility Name
Azienda Ospedaliera Città della Salute e della Scienza di Torino
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10126
Country
Italy
Facility Name
Az. Osp. Pisana Ospedale S. Chiara; U.O. Di Reumatologia
City
Pisa
State/Province
Toscana
ZIP/Postal Code
56100
Country
Italy
Facility Name
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Clinica Universitaria de Navarra; Servicio de Oncologia
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Facility Name
Hospital Clinic i Provincial; Servicio de Farmacia
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Institut Catala d Oncologia Hospital Duran i Reynals
City
Barcelona
ZIP/Postal Code
08908
Country
Spain
Facility Name
Hospital Ramon y Cajal; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
HUG; Oncologie
City
Geneve
ZIP/Postal Code
1211
Country
Switzerland
Facility Name
Universitätsspital Zürich; Klinik für Neurologie
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland
Facility Name
Bristol Haematology and Oncology Centre
City
Bristol
ZIP/Postal Code
BS2 8ED
Country
United Kingdom
Facility Name
Sarah Cannon Research Institute
City
London
ZIP/Postal Code
W1G 6AD
Country
United Kingdom
Facility Name
Nottingham City Hospital; David Evans Centre
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
We'll reach out to this number within 24 hrs